tryprostatin-a and Breast-Neoplasms

tryprostatin-a has been researched along with Breast-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for tryprostatin-a and Breast-Neoplasms

ArticleYear
Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein.
    Bioorganic & medicinal chemistry, 2008, Apr-15, Volume: 16, Issue:8

    Tryprostatin A is an inhibitor of breast cancer resistance protein, consequently a series of structure-activity studies on the cell cycle inhibitory effects of tryprostatin A analogues as potential antitumor antimitotic agents have been carried out. These analogues were assayed for their growth inhibition properties and their ability to perturb the cell cycle in tsFT210 cells. SAR studies resulted in the identification of the essential structural features required for cytotoxic activity. The absolute configuration L-Tyr-L-pro in the diketopiperazine ring along with the presence of the 6-methoxy substituent on the indole moiety of 1 was shown to be essential for dual inhibition of topoisomerase II and tubulin polymerization. Biological evaluation also indicated the presence of the 2-isoprenyl moiety on the indole scaffold of 1 was essential for potent inhibition of cell proliferation. Substitution of the indole N(a)-H in 1 with various alkyl or aryl groups, incorporation of various L-amino acids into the diketopiperazine ring in place of L-proline, and substitution of the 6-methoxy group in 1 with other functionality provided active analogues. The nature of the substituents present on the indole N(a)-H or the indole C-2 position influenced the mechanism of action of these analogues. Analogues 68 (IC(50)=10 microM) and 67 (IC(50)=19 microM) were 7-fold and 3.5-fold more potent, respectively, than 1 (IC(50)=68 microM) in the inhibition of the growth of tsFT210 cells. Diastereomer-2 of tryprostatin B 8 was a potent inhibitor of the growth of three human carcinoma cell lines: H520 (IC(50)=11.9 microM), MCF-7 (IC(50)=17.0 microM) and PC-3 (IC(50)=11.1 microM) and was equipotent with etoposide, a clinically used anticancer agent. Isothiocyanate analogue 71 and 6-azido analogue 72 were as potent as 1 in the tsFT210 cell proliferation and may be useful tools in labeling BCRP.

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Indole Alkaloids; Molecular Structure; Piperazines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tubulin

2008
Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A.
    International journal of cancer, 2003, Dec-10, Volume: 107, Issue:5

    MDR in human cancers is one of the major causes of failure of chemotherapy. A member of the superfamily of ABC transporters, BCRP, was demonstrated to confer an atypical MDR phenotype to tumor cells. To overcome the BCRP-mediated drug resistance, the fungal secondary metabolite TPS-A, a diketopiperazine, was analyzed with regard to its potency to reverse the BCRP-mediated drug-resistant phenotype. At concentrations of 10-50 microM, TPS-A reversed a mitoxantrone-resistant phenotype and inhibited the cellular BCRP-dependent mitoxantrone accumulation in the human gastric carcinoma cell line EPG85-257RNOV, the human breast cancer cell line MCF7/AdrVp (both exhibiting acquired BCRP-mediated MDR) and the BCRP cDNA-transfected breast cancer cell line MCF-7/BCRP clone 8. No cytotoxicity was seen at effective concentrations. These data indicate that TPS-A is a novel BCRP inhibitor.

    Topics: Acridines; Antineoplastic Agents; Breast Neoplasms; Cell Division; Daunorubicin; Drug Resistance, Multiple; Female; Humans; Indole Alkaloids; Kinetics; Mitoxantrone; Piperazines; Stomach Neoplasms; Tetrahydroisoquinolines; Tumor Cells, Cultured

2003